Replimune Group AI Stock Analysis
Replimune Group (7R8) AI Stock Analysis
Replimune Group
(Frankfurt:7R8)
No summary available
Replimune Group (7R8) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 2.06B
- Dividend Yield
- ―
- Average Volume (3M)
- 153
- Price to Earnings (P/E)
- -7.8
- Beta (1Y)
- 0.92
- Revenue Growth
- ―
- EPS Growth
- 23.22%
- Country
- Germany
- Employees
- 465
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Replimune Group Business Overview & Revenue Model
Company Description
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic cand...
Replimune Group Earnings Call Summary
The call was strongly optimistic about TUDRIQEV's early commercial launch, with rapid account engagement, formulary additions, prescriptions, payer coverage, next-day delivery, and adoption across both academic and regional centers. The company also reported a stronger cash position and improved sequential net loss. Offsetting concerns were the absence of current-quarter product revenue, continued operating losses, higher SG&A tied to launch activities, lack of revenue guidance, and limited visibility into patient volumes and real-world treatment economics. Overall, the positive launch commentary and early adoption metrics significantly outweighed the stated challenges.
Q2-2027 Updates
Positive Updates
Negative Updates
Company Guidance
Management will not be providing revenue guidance at this time; the list price of TUDRIQEV is $450,000 per course of therapy before customary rebates and discounts, patients may receive 8 or more cycles, and revenue from a patient starting therapy may be recognized over more than 1 quarter. Replimune expects its cash position to fund operations for greater than 12 months, anticipates having a permanent J-code in place by April 2027, and said it could sort of double the number of accounts already initiating patients by the end of the year. The company’s priority in the first 6 months is the top 200 accounts, representing about 30% of melanoma patients treated nationally each year, followed by the next wave of 250 accounts representing another 20% of the melanoma population; it will continue to assess accelerating into these accounts and the community.
Replimune Group Risk Analysis
Replimune Group disclosed 60 risk factors in its most recent earnings report. Replimune Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksReplimune Group Peers Comparison
Overall Rating
LYEL53Neutral
IMTX48Neutral
CTMX47Neutral
CADL42Neutral
ARTV40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| LYEL | 53Neutral | $411.81M | -1.07 | -107.62% | ― | -63.41% | 49.87% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| IMTX | 48Neutral | $960.66M | -3.61 | -52.19% | ― | -44.50% | -80.18% |
| CTMX | 47Neutral | $431.65M | -4.72 | -33.97% | ― | -87.66% | -210.45% |
| CADL | 42Neutral | $715.45M | -6.54 | -89.38% | ― | ― | -108.75% |
| ARTV | 40Underperform | $200.70M | -1.36 | -45.32% | ― | ― | 7.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:7R8 | Replimune Group | 19.36 | 11.76 | 154.74% | |
| CTMX | CytomX Therapeutics Inc. | 2.13 | -1.73 | -44.82% | |
| IMTX | Immatics N.V. | 6.69 | -3.29 | -32.97% | |
| LYEL | Lyell Immunopharma, Inc. | 16.86 | -0.55 | -3.16% | |
| CADL | Candel Therapeutics, Inc. | 9.22 | 4.61 | 100.00% | |
| ARTV | Artiva Biotherapeutics, Inc. | 4.07 | 0.68 | 20.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.